Antimicrobial pharmacology, selection, dosing and stewardship in children — formative SAQs

1. Developmental pharmacokinetics in the neonate

This neonate has immature drug clearance because both GFR and hepatic enzyme activity are low at 30 weeks corrected gestation. Vancomycin — renally cleared — has a prolonged half-life, so the dosing interval must be extended to avoid accumulation and nephrotoxicity. Gentamicin — also renally cleared — has a larger volume of distribution in neonates (due to high total body water and extracellular fluid) but slower clearance, so the interval is individualised by gestational and postnatal age. The practical consequence is that both drugs need age-adjusted intervals, not standard older-child or adult intervals scaled by weight. ^{[15] [16]}

2. Vancomycin dosing and AUC monitoring in the 4-year-old

I would prescribe vancomycin at a weight-based dose calculated for 15 kg, using the current institutional protocol. For serious MRSA infection, the target is an AUC₂₄/MIC of 400 or more, which better predicts efficacy while reducing nephrotoxicity compared to trough-only monitoring. The 2020 consensus guideline from ASHP, IDSA, PIDS, and SIDP recommends AUC-guided monitoring over trough-only strategies. Critically ill children may have augmented renal clearance, producing unexpectedly low levels on standard doses and requiring individualised adjustment. ^[3]

3. Extended-interval aminoglycoside dosing

Aminoglycosides are concentration-dependent killers with a significant post-antibiotic effect: a high peak maximises bacterial kill, and suppression continues after the level falls below the MIC. Once-daily dosing maximises the peak-to-MIC ratio, minimises renal tubular accumulation, and reduces nephrotoxicity risk. Meta-analyses in both children and neonates confirm that extended-interval dosing is as effective as traditional multiple-daily dosing with no increase in oto- or nephrotoxicity. ^[5]

4. WHO AWaRe-guided empiric selection

For a previously well child with community-acquired pneumonia, I would start with a WHO Access-group antibiotic — oral amoxicillin as first-line, which has a narrow spectrum, low resistance potential, and proven efficacy. The AWaRe target is for at least 60 per cent of total antibiotic use to come from the Access group. A Watch-group agent (such as azithromycin for atypical cover) is reserved for specific indications or treatment failure. Reserve-group agents have no role in uncomplicated community-acquired pneumonia. ^{[2] [8]}